Alcidion Group (ASX:ALC) - Managing Director, Kate Quirke
Managing Director, Kate Quirke
Source: Finfeed
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) has signed a 12-month, $560,000 contract with Sydney Local Health District (LHD) for its Miya Precision platform
  • Miya Precision combines AI-based predictive analysis, clinical support, and mobile alerts in an easy-to-use dashboard
  • This contract will see Miya Precision be deployed to Sydney LHD’s virtual hospital which is being used for COVID-19 positive patients who are in home isolation
  • Patients will have their statuses displayed in real-time, as well as other relevant information to allow for the best possible care
  • Alcidion is up 10.3 per cent on the market and shares are currently trading for 16 cents each

Alcidion Group (ALC) has signed a 12-month, $560,000 contract with Sydney Local Health District (LHD) for its Miya Precision platform.

Miya Precision combines AI-based predictive analysis, clinical support, and mobile alerts in an easy-to-use dashboard.

This contract will see the Miya Precision platform be deployed to Sydney LHD’s virtual hospital, rpavirtual, which is being used for COVID-19 positive patients who are in home isolation.

“Miya Precision has the potential to provide valuable support for some critical short-term requirements for Sydney LHD, but also provides us with a platform to continue to innovate the delivery of patient care across the entire district,” Sydney LHD Chief Information Officer Richard Taggart said.

Patients will have their statuses displayed in real-time, as well as other relevant information to allow for the best possible care.

This reduces the risk of infection for healthcare workers, and the need for personal protective equipment (PPE).

“We are delighted to enter into this partnership with Sydney LHD. We have moved quickly to enable an initial rollout that addresses the short-term challenges raised by COVID-19,” Alcidion Managing Director Kate Quirke commented.

“The engagement allows us to demonstrate the value of our platform in one of the busiest hospitals in Australia operating across metropolitan Sydney, in the same way as we have done with the deployment at Murrumbidgee LHD for the rural sector,” she added.

Alcidion is up 10.3 per cent on the market and shares are trading for 16 cents each at 1:39 pm AEST.

ALC by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…